Curated News
By: NewsRamp Editorial Staff
April 07, 2026
Aclarion's Nociscan Gains Traction at London Clinic, Aiding Back Pain Diagnosis
TLDR
- Aclarion's Nociscan adoption at The London Clinic offers a diagnostic edge, potentially improving surgical success rates up to 97% for chronic low back pain treatment.
- Nociscan uses MR spectroscopy and proprietary AI algorithms to analyze chemical biomarkers, helping physicians differentiate painful from non-painful lumbar discs non-invasively.
- Nociscan provides objective data to improve clinical decisions, potentially enhancing treatment outcomes for millions suffering from chronic low back pain worldwide.
- Aclarion's Nociscan technology leverages chemical biomarkers and AI to non-invasively pinpoint disc pain, with nearly 100 scans performed at The London Clinic.
Impact - Why it Matters
Chronic low back pain is a pervasive and often debilitating condition affecting hundreds of millions globally, frequently leading to significant healthcare costs, lost productivity, and reduced quality of life. Traditional diagnostic methods like MRI can show structural issues but don't always pinpoint the specific source of pain, sometimes resulting in ineffective treatments or unnecessary procedures. Nociscan's technology aims to bridge this diagnostic gap by providing biochemical evidence of disc pain. Its growing adoption at a leading clinic like The London Clinic suggests it is moving from a novel concept to a practical clinical tool. For patients, this could mean more accurate diagnoses, better-targeted treatments (potentially including more successful surgeries), and reduced trial-and-error in managing their pain. For the healthcare system, it offers the potential to improve treatment outcomes and optimize resource allocation by ensuring interventions are directed where they are most likely to be effective.
Summary
Aclarion, Inc., a commercial-stage healthcare technology company, has announced the release of a new video featuring Mr. John Sutcliffe, a Consultant Spinal Neurosurgeon and Lead Clinician at The London Spine Clinic within The London Clinic, one of the UK's leading private hospitals. The video highlights his real-world clinical experience using the company's diagnostic platform, Nociscan, to evaluate patients with chronic low back pain. Sutcliffe, with over 30 years of experience treating complex spinal cases, emphasizes that Nociscan provides an additional, objective layer of insight that complements traditional imaging, helping to inform clinical decisions and improve physician confidence.
The announcement underscores the growing adoption of Nociscan in clinical practice, with nearly 100 scans already performed at The London Clinic. Nociscan is a non-invasive, SaaS-based solution that leverages MR spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain in the lumbar spine, helping physicians differentiate between painful and non-painful discs. Brent Ness, Aclarion's Chief Executive Officer, noted that approaching 100 scans at such a prestigious international center is a significant indicator of increasing adoption and reinforces Nociscan's potential as a valuable tool in the evaluation of a condition that affects approximately 266 million people worldwide. Clinical data has demonstrated that when used alongside other diagnostic tools, treating all Nociscan-positive discs can lead to surgical success rates as high as 97%.
For more News from Aclarion, readers can visit the company's news page. The video itself is available for viewing online, providing a compelling perspective on the technology's integration into day-to-day practice. This development marks a notable step for Aclarion as it commercializes its augmented intelligence platform to address a major global healthcare challenge. The company's technology represents an innovative approach to personalizing treatment strategies for chronic low back pain, a condition often difficult to diagnose precisely with conventional methods alone.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, Aclarion's Nociscan Gains Traction at London Clinic, Aiding Back Pain Diagnosis
